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Background: We examined the phenotype and function of lymphocytes collected from the peripheral blood (PBL)
and tumor (TIL) of patients with two different solid malignancies: colorectal cancer liver metastases (CRLM) and
ovarian cancer (OVC).
Methods: Tumor and corresponding peripheral blood were collected from 16 CRLM and 22 OVC patients; immediately
following resection they were processed and analyzed using a multi-color flow cytometry panel. Cytokine mRNA from
purified PBL and TIL CD4+ T cells were also analyzed by qPCR.
Results: Overall, we found similar changes in the phenotypic and cytokine profiles when the TIL were compared to
PBL from patients with two different malignancies. The percentage of Treg (CD4+/CD25+/FoxP3+) in PBL and TIL was
similar: 8.1% versus 10.2%, respectively in CRLM patients. However, the frequency of Treg in primary OVC TIL was higher
than PBL: 19.2% versus 4.5% (p <0.0001). A subpopulation of Treg expressing HLA-DR was markedly increased in TIL
compared to PBL in both tumor types, CRLM: 69.0% versus 31.7% (p = 0.0002) and OVC 74.6% versus 37.0% (p <0.0001),
which suggested preferential Treg activation within the tumor. The cytokine mRNA profile showed that IL-6, a cytokine
known for its immunosuppressive properties through STAT3 upregulation, was increased in TIL samples in patients
with OVC and CRLM. Both TIL populations also contained a significantly higher proportion of activated CD8+ T cells
(HLA-DR+/CD38+) compared to PBL (CRLM: 30.2% vs 7.7%, (p = 0.0012), OVC: 57.1% vs 12.0%, (p <0.0001)).
Conclusion: This study demonstrates that multi-color flow cytometry of freshly digested tumor samples reveals
phenotypic differences in TIL vs PBL T cell sub-populations. The TIL composition in primary and metastatic tumors
from two distinct histologies were remarkably similar, showing a greater proportion of activated/suppressive Treg
(HLA-DR+, CD39+, CTLA-4+ and Helios+) and activated cytotoxic T cells (CD8+/HLA-DR+/CD38+) when compared
to PBL and an increase in IL-6 mRNA from CD4 TIL.
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Tumor immunotherapy has emerged as an important
treatment modality for cancer patients. Historically, melan-
oma and renal cell carcinoma have been described as tu-
mors that respond to immunotherapy. However, recent
clinical trials have shown that a variety of other tumor
types are also responding to immunotherapy [1-3].
The mechanism(s) of tumor rejection following immuno-
therapy treatment have been difficult to define. Until re-
cently, most immunologic analyses in cancer patients have
been conducted on PBL or tissue sections, where samples
are more easily obtained. However, it is the composition of
the immune cells at the tumor site that is likely to be most
important; and the tumor infiltrating lymphocytes (TIL)
may be quite different from the PBL. Furthermore it is
extremely hard to perform immune subset analyses by
immunohistochemistry. Therefore to gain a deeper un-
derstanding of how immunotherapy could potentially affect
the tumor microenvironment, it would be important to first
characterize the subset distribution and phenotype of the
immune cells in progressively growing tumors.
The purpose of this study was to compare the pheno-
type and function of freshly isolated TIL to PBL in patients
with progressively growing tumors by flow cytometry. Sev-
eral studies, using primarily immunohistochemistry, have
shown that greater frequencies of Treg cells within the
tumor environment leads to a decrease in patient survival
[4,5]. Increased Treg inhibitory function has been associ-
ated with increases in several surface and/or intra-cellular
markers. Treg cells with the greatest suppressive capacity
express high levels of HLA-DR and CD39 on their surface
and a decline in this population has been associated with
renal graft rejection or premature delivery [6,7]. In con-
trast to Treg frequency and phenotype, increased levels of
CD8+ T cells in TIL has been associated with a positive
clinical outcome in patients with CRC [4]. However, these
studies did not examine the activation status of CD8+ T
cells. We have used the co-expression of HLA-DR and
CD38 as well as the proliferation marker Ki-67 to deter-
mine the activation status of CD8+ T cells isolated from
TIL vs blood.
In this study, we analyzed fresh tumor and paired periph-
eral blood samples from patients with CRC and OVC; we
compared the function and phenotype of lymphocytes from
TIL to those in peripheral blood. The first group was com-
posed of patients undergoing resection of colorectal cancer
liver metastases (CRLM), while the second enrolled women
undergoing cytoreductive surgery for ovarian cancer.
CRC is the third most common cause of cancer-related
deaths worldwide and liver is the most common site of this
metastatic disease. Fifteen percent of patients with CRC,
are diagnosed with liver metastasis at the same time as
their primary tumor and another 15% will develop liver
metastases after resection of the primary tumor [8].Surgical resection is the primary treatment option for oper-
able metastases but is associated with a recurrence rate of
50-90% [9-11]. The medical treatment after surgical resec-
tion has traditionally been cytotoxic chemotherapy and re-
cent studies have suggested that the immune response has
important prognostic implications for CRC patients [5,12].
Ovarian Cancer represents only 3% of female cancers,
but it is the fifth leading cause of cancer-related death
in women. Most patients are diagnosed in advanced stage
(spread beyond the pelvis, 75%) due to lack of effective early
detection strategies. Surgical debulking is the standard of
care followed by chemotherapy with paclitaxel and car-
boplatin. Unfortunately, the relapse rate after treatment
is high, up to 75%. Many different strategies have been
attempted to reduce relapse rates with little success. Sev-
eral studies summarized in a meta-analysis by Hwang
et al. [13], have suggested that the composition of TIL also
has prognostic significance.
The results of this study demonstrate that the compos-
ition of T lymphocytes within CRLM and ovarian tumors
is significantly different than peripheral blood T lympho-
cytes from the same patient. Within the tumor microenvir-
onment, there was a significant increase in both activated
Treg and activated CD8+ T cells. Moreover, we found that
regardless of the tumor type, tumor location, or whether
the tumor was a primary or metastatic deposit, the




From September 2009 to September 2012, under the
approval of our institute’s Institutional Review Board
(Providence Portland Medical Center, IRB), 16 patients
with CRLM (Table 1) and 22 patients with OVC were en-
rolled in the study. Biopsy specimens and body fluids were
received and processed as described in Methods. CRLM
patient’s age ranged from 30 to 84 years with a median of
67 years. The male to female ratio was 1:1. The primary
CRC tumor was resected between 10 to 51 months prior to
the resection of CRLM, with a median of 20 months. OVC
patients’ age ranged from 51 to 88 years with a median of
63.5 years. The majority of patients were diagnosed with
serous carcinoma 17/22. Two were diagnosed with endro-
metroid adenocarcinoma, two with peritoneal carcinoma
(1 serous and 1 Muellerian) and one with carcinosarcoma.
None of the OVC patients were pre-treated prior to
obtaining the tumor resections hence the OVC patients
were not included in Table 1.
T cell composition: PBL versus TIL
TIL isolation was successful for majority of tumor samples
obtained. CRLM (n = 16) had fewer cells/gram of tissue
compared to the OVC samples (n = 21) (median 1.5×106
Table 1 Patient’s characteristics















CRI 1010 60 F 3 0 0 None Bevacizumab, Oxaliplatin,
Capecitabine
49
CRI 1012 53 M 3 0 0 5FU + Leukovorin FOLFOX + avastin 209
CRI 1091 60 M 3 2 1 FOLFOX FOLFOX 52
CRI 1101 47 F 3 1 1 FOLFOX + avastin FOLFOX + avastin 36
CRI 1109 70 M 4 1 1 XELOX XELOX 52
CRI 1102 55 M 3 2 1 FOLFOX + avastin FOLFOX + avastin 133
CRI 1126 60 F 3 1 1 FOLFOX FOLFOX + avastin 487
CRI 1129 79 M None Capecitabine 53
CRI 1109 70 M 4 1 1 XELOX XELOX 123
CRI 1208 83 F 3 1 0 XELOX FOLFIRI + avastin 103
CRI 1109 70 M 4 1 1 n/a n/a n/a
CRI 1197 73 F 1 FOLFOX FOLFOX 89
CRI 1400 77 M 3 0 1 Modified FOLFOX None 185
CRI 1405 33 F 3 0 1 FOLFOX FOLFOX 36
CRI 1404 50 F 3 0 0 None FOLFOX 35
CRI 1513 29 F 4a 2b 0 FOLFOX None None
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CD3+ T cells after ficoll separation were 28.2% in primary
OVCs, 53.1% within the omental metastases, 64.3% within
ascites and 47.5% from PBMC (Tables 2 and 3). The per-
centage of CD3+ T cells from CRLM within the lympho-
cyte gate were, 35.8% for TIL and 53% for PBMC. The
percentage of CD3+ T cells was calculated as a percentage
of a standard FSC and SSC lymphocyte gate [14]. Within
the CD3+ T cell population, CD4+ T cells represented
42.4% of the OVC primary tumor, 48.2% of the omental
metastases and 49.8% of the CRLM TIL. Approximately
30% of the infiltrating lymphocytes in all tumor samples
were CD8+ T cells, 30.8% for CRLM, 34.5% for primary
OVC, 33.4% for omental metastases and 31.4% for ascites.
The median CD4/CD8 ratio in the blood was very similar
for both groups of patients (2.4 and 2.3). The median
CD4/CD8 ratio was lower in T cells isolated from tumors
(1.6 for CRLM, 1.3 for OVC primaries, 1.4 for omental
mets and 1.3 for ascites). Detailed flow cytometric analyses
of CD4+ and CD8+ T cells with other markers were per-
formed as described in Additional file 1: Figure S1. ThisTable 2 T cell distribution in CRLM
CRC liver metastasis Median (25th-75th percentile) percentages
Cells Blood (n = 16) TIL (n = 16)
CD3+ T cells 53.0 (44.2-60.6) 35.8 (16.0-42.0)
CD4+ T cells 56.45 (51.4-73.6) 49.75 (32.1-53.9)
CD8 + T cells 21.15 (14.6-36.7) 30.75 (22.1-37.2)
CD4:CD8 ratio 2.4 (1.4-4.7) 1.6 (0.9-2.3)scheme was throughout the entire manuscript to calculate
percentages in each group.
Characterization of CD4+ T cell
A representative dot plot analysis for CD4+ cells from an
OVC sample is shown in Figure 1A. Using the gating
scheme in Figure 1A we found that the mean percentage
of CD4+ CD25+ FoxP3+ Treg within primary and omental
mets in ovarian cancer patients were significantly increased
compared to PBL (Figure 1C); however, in CRLM patients
there was no significant difference in the mean percentage
of Treg in TIL compared to blood (8.1% and 10.2% re-
spectively, Figure 1B). We observed that the mean percent-
age of Treg in the peripheral blood was lower in OVC
compared to CRC patients (4.5% vs 8.1%) (Figure 1B-C).
However, the mean percentage of Treg within the primary
or the omental OVC metastases was 4 times greater than
the blood, reaching an average of 19.2% and 18.7% of
CD4+ T cells respectively (Figure 1C). We also assessed
Ki-67 expression (proliferation marker) in Treg within the
2 groups of patients, (Figure 1A, D-E). As shown in
Figure 1D and E, the percentage of dividing Treg was
similar in the tumors and peripheral blood for both tumor
types.
The phenotype of CD4+ CD25+ FoxP3+ T cells: TIL versus
PBMC
Since there are subtypes within Treg, that exhibit differing
abilities to suppress T cell function, we determined whether
the presence of these sup-phenotypes differed by location
Table 3 T cell distribution in OVC tumor specimens
Ovarian Median (25th-75th percentile) percentages
Cells Blood (n = 21) Ascites (n = 16) TIL (n = 21) Met (n = 17)
CD3+ T cells 47.5 (31.5-62.0) 64.30 (40.2-75.2) 28.2 (17.8- 52.3) 53.1 (25.1-62.3)
CD4+ T cells 62.3 (51.9-73.8) 49.0 (35.9-64.5) 42.4 (36.1-45.1) 48.2 (40.8-53.3)
CD8+ T cells 25.1 (18.7-36.6) 31.4 (25.8-48.5) 34.5 (22.6-47.5) 33.4 (23.1-39.0)
CD4:CD8 ratio 2.3 (1.4-4.0) 1.3 ( 0.8-2.5) 1.3 (0.8-1.8) 1.4 (1.1-2.0)
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sion is a signature of activation for both Treg and effector
CD4+ T cell populations we assessed its expression on TIL
and PBL. As shown in Figure 2A and B, Treg present
in the primary tumors and mets have increased HLA-DRFigure 1 CD4+ T cell analysis. A. CD3+ CD4+ T cells collected from PBL, a
and FoxP3, upper panels and Ki-67 and Foxp3, lower panels. Percentage of
OVC patients (n = 22) C. Percentage of proliferating Treg in CRC samples (Dexpression compared to PBL for both CRC and OVC
patients (69% and 70% compared to 31.7 and 37% respect-
ively). We also found that the frequency of non-Treg/
effector CD4+ T cells expressing HLA-DR is increased
in the TIL compare to blood (Figure 2C). However, thescites, primary tumor and omental metastases were analyzed for CD25
CD25+ FoxP3+, Treg in PBL and TIL of CRC patients (n = 16) B, and in
) and in OVC samples (E).
Figure 2 HLA-DR expression on Treg and non-Treg CD4+ T cells. CD3+ CD4+ CD25+ FoxP3+ Treg cells were analyzed for HLA-DR expression
in CRC samples (A) and OVC samples (B). C. HLA-DR expression on CD4+ Foxp3− non-Treg in OVC samples.
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significantly greater in the Treg TIL compared to the
conventional CD4+ TIL, 4225.8 and 4566.7 for primary
tumor and omental metastases Treg compared to 2976.5
and 2639.8 for conventional CD4+ TIL in primary tumor
and omental metastases (p = 0.0006 and <0.0001, respect-
ively) (data not shown). The data suggest that the Treg
within the tumor are more activated than the conventional
CD4+ TIL within these progressively growing tumors.
Given that CRLM and OVC patients have a very differ-
ent treatment and clinical history it was somewhat sur-
prising that the increase in HLA-DR expression by Treg
from tumors was consistent for both of these tumor types
(Figure 2A-B). We further investigated whether other
markers known to be expressed by activated Treg, were
upregulated in the tumor microenvironment. We exam-
ined CD39, CTLA-4 and Helios all of which have been
associated highly suppressive Treg activity. CD39 is an
ectonucleoside triphosphate diphosphohydrolase, that
hydrolases ATP and thus depletes ATP from the extra-
cellular milieu and has been associated with highly suppres-
sive Treg function [15,16]. Helios has been characterized as
a Treg lineage marker and is a transcription factor that has
also been associated with greater suppressive activity [17].
Fifteen OVC samples were analyzed for the expression of
Helios and the frequency of Helios expressing Treg was
significantly higher in the OVC primary tumors and
omental metastases when compared to PBL (79.6, 76.2
versus 50.1%) (Figure 3A). Co-expression of HLA-DR
and Helios was also higher on Treg from TIL (57.5%) and
omental metastases (58.8%) compared to blood (23.6%) or
ascites (34.7%) (Figure 3B-C). Eleven OVC samples were
assessed for CD39 expression. Between 60-70% of Treg iso-
lated from primary tumors and omental metastases were
positive for CD39, while only 30% of the PBL Treg were
positive for CD39 (Figure 3D-E). The MFI of CD39 was
also significantly higher on Treg collected from TIL
and Met compared to PBL (1842.5, 964.1 vs 441.9, with
a p <0.001 and <0.05 respectively) (data not shown).
When we assessed CD39 on the non-Treg CD4, 32.7%of TIL non-Treg CD4+ T cells expressed CD39 compared
to 10.6% of PBL non-Treg CD4+ T cells (p <0.05) (data not
shown). The CD39 MFI was greater on Treg compared to
non-Treg CD4 T cell population. Co-expression of HLA-
DR and CD39 was found on 50% of the Tregs within the
primary tumors and Mets while only 20% of PBL Treg co-
expressed these two markers (Figure 3E). Another in-
hibitory protein, CTLA-4 is expressed by both effector
and regulatory T cells and it is known for suppressing
T cell function [18]. There was no significant difference
in percentage of Treg that expressed CTLA-4 in PBL,
primary tumor and metastases Treg (Figure 3F). However,
the co-expression of CTLA-4 and CD39 is signifi-
cantly higher in the TIL (61.2%) compared to PBL (20.3%)
(Figure 3G and Tables 4 and 5).
HLA-DR+ Treg isolated from tumors have greater
suppressive function
We obtained sufficient surgical material from two OVC
patients to compare the ability of HLA-DR+ and HLA-DR−
Treg to suppress IFNγ production from activated periph-
eral blood CD4 T cells. CD3 enriched T cells from tumors
were stained with anti-CD4, anti-CD25, anti-CD127 and
anti-HLA-DR and were gated on the CD25hi CD127lo
CD4+ T cells, which identifies the Treg population in tu-
mors [19,20]. These cells were then sorted into HLA-DR
positive and negative subsets and their ability to inhibit T
cell function was assessed. The HLA-DR+ Treg were 2–4
times more suppressive than HLA-DR− Treg as measured
by the inhibition of IFNγ secretion by activated CD4 T cells
(Figure 4A-B and Additional file 2: Figure S2). These results
are supportive of recent manuscripts [21,22] showing that
the tumor microenvironment is greatly enriched for highly
active Treg and this population most likely plays a role in
dampening effector T cell responses within the tumor.
Characterization of CD8+ TIL
CD8+ T cell immune infiltrates have been characterized
in several different human tumor types [4]. In CRC, an
increase in CD8+ infiltrates in the primary tumor has been
Figure 3 Expression of markers characterizing more suppressive Treg. Panel A shows the expression of Helios CD39 and CTLA-4 on CD4+
CD25+ Foxp3+ Treg from an OVC sample. B. Expression of Helios on Treg cells. C. Co-expression of Helios and HLA-DR on Treg (OVC n = 17).
D. Percentage of CD39+ Treg, E. Percentage of CD39-HLA-DR Treg (OVC n = 11). F. CTLA-4 expression and G. CD39-CTLA-4 expression on Treg
from OVC samples (n = 10).
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tumor progression [23,24]. The majority of these studies
used IHC to assess cellular infiltrates [23,24] and very few
studies describe complex CD8 phenotype and proliferative
status of CD8 T cells isolated from tumors. In this study,
we focused on co-expression of the membrane-bound ac-
tivation markers CD38 and HLA-DR expressed on CD8+
T cells. Co-expression of these two proteins has been used
to identify Ag-activated vaccine-specific CD8+ T cells in
humans that had recently been inoculated with a yellow-
fever vaccine [25]. Hence in the context of tumor infiltrat-
ing lymphocytes co-expression of these to markers may
identify recently activated tumor-antigen specific T cells.
The percentage of CD38+/HLA-DR+ CD8+ T cells in the
peripheral blood of CRLM and OVC patients was low, be-
tween 8-10%. In both CRLM and OVC the percentage ofTable 4 Percentage distribution of CD4+ T cell phenotypes:
summary of CD4+ T cells phenotypes in CRLM patients
Mean% cell population (+/− SD) PBL TIL
CD25+ Foxp3+ CD4+ T cells 8.1 (+/− 3.0) 10.2 (+/− 8.0)
Ki-67+ Treg cells 17.9 (+/− 7.6) 13.5 (+/− 9.4)
HLA-DR + Treg cells 31.7 (+/− 13.5) 69.4 (+/− 13.5)CD38+/HLA-DR+ CD8+ T cells is increased five-fold and
four-fold in TIL compared to PBL in ovarian cancer and
CRC patients, respectively (Figure 5D-E). We also assessed
Ki-67 expression to determine the proportion of dividing
CD8+ T cells in both tumor types. The frequency of
dividing PBL CD8+ T cells in both patient groups is ap-
proximately 3% (Figure 5A-C). However, the frequency of
Ki-67+ CD8+ T is significantly higher in the tumors from
CRLM patients, 9.1% and in the OVC primary tumors and
omental metastases, 12.3% and 12.5% respectively, com-
pared to PBL.
Cytokine mRNA levels in CD4 T Cells from TIL versus PBL
CD4+ T cells were enriched from both PBL and TIL as
described in Methods. The purity of CD4+ T cells was
between 85-95%. Cytokine mRNA was quantitated by
PCR to investigate whether there were any differences in
cytokine RNA obtained from blood versus tumor CD4+
T cells. No differences were observed for IL-2, INFγ,
TGFβ, IL-3, IL-4 or IL-10 and very low levels of IL-
17A and IL-21 mRNA were detected in both PBL and
TILs. However, IL-6 mRNA was detected at high levels
from CD4+ TIL when compared to PBL of the same pa-
tients (Figure 6). Quantitative PCR assessment for IL-6 in
Table 5 Percentage distribution of CD4+ T cell phenotypes: summary of CD4+ T cells phenotypes in OVC patients
Mean% cell population (+/− SD) PBL Ascitis TIL Met
CD25+ Foxp3+ CD4+ T cells 4.6 (+/− 3.4) 10.31 (+/− 4.4) 19.7 (+/−10.1) 19.8 (+/− 11.4)
Ki-67+ Treg cells 13.9 (+/− 8.2) 18.2 (+/− 12) 20.4 (+/−10.2) 22 (+/−11.3)
HLA-DR + Treg cells 37.4 (+/− 17.4) 47.0 (+/− 14.1) 74.6 (+/− 12.1) 75.1 (+/− 8.3)
HLA-DR + CD4+ T cells 7.6 (+/− 7.7) 25.5 (+/− 17.3) 48 (+/− 20.6) 42.7 (+/−18.2)
Helios + Treg cells 50.7 (+/− 19.8) 58.7 (+/− 27.1) 77.2 (+/− 12.6) 76.3 (+/− 11.0)
HLA-DR + Helios + Treg cells 24.1 (+/− 7.7) 35.1 (+/−15.9) 59.2 (+/− 14.2) 62 (+/− 8.7)
CD39+ Treg cells 29.1 (+/− 16.7) 43.1 (+/− 20.9) 72.2 (+/− 21.1) 67.5 (+/− 23.7)
HLA-DR + CD39+ Treg cells 21.1 (+/− 15) 28.8 (+/− 15) 54.4 (+/− 19.3) 53.4 (+/− 18.1)
CTLA-4 Treg cells 50.6 (+/− 27.8) 63.8 (+/− 28) 81.6 (+/− 14.9) 77.1 (+/− 20.2)
CD39+ CTLA-4+ Treg cells 18.5 (+/− 17.8) 27.2 (+/− 14.2) 61.7 (+/− 20.3) 53.6 (+/− 23)
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increases in IL-6 mRNA production by CD4+ T cells when
TIL were compared to PBL. In 7 out of 14 OVC patients
samples, there was an increase in IL-6 mRNA both within
the primary tumors and metastases when compared to
blood, 4/14 revealed an increase in the metastases but not
the tumor and for 3/14 there was no difference when
comparing the blood, tumor and metastases. The fold-
increase varied from 5-fold up to over a 1000-fold in-
crease and the average was 12-fold. In the 10 CRC sam-
ples analyzed, 8 out of 10 revealed increased levels of
IL-6 mRNA in TIL compared to blood. Similar to the
ovarian cancer samples, the fold-increases varied from 2
to over a 1000-fold (average increase was 120-fold). We
also quantified IFN-γ message from all the samples shown
in Figure 6. As opposed to IL-6 no difference for IFN-γ
mRNA was observed when comparing CD4 TIL to PBL
within the same patient (data not shown).
Discussion
This work demonstrates the utility of using a 10 color flow-
cytometry panel for analyzing TIL from freshly isolated
tumor samples and shows that extensive information canFigure 4 HLA-DR + TIL Treg have a higher suppressive potency. CD3+
suppressive function was measured in vitro by their capacity to suppres
individual OVC patients.be obtained using this approach. 10-color flow cytometry
allows for a more detailed phenotypic characterization of T
cell subsets when compared to standard IHC techniques,
which have been used in previous TIL studies [26]. These
analyses show several significant phenotypic differences
in the composition of TIL when compared to PBL. Our
results also suggest, that regardless of the tumor type
(CRC and OVC), the site of the disease (primary or meta-
static lesions), or treatment status, the composition of TIL
was surprisingly similar in these progressively growing tu-
mors. We will began exploring other human malignancies
in the future to ascertain whether this phenotypic pattern
holds true across several different tumor types.
When comparing the TIL immune phenotype to PBL, we
found several significant differences. OVC TIL contained a
higher percentage of Treg compared to PBL (4.6% PBL
compared to 19.7%), while there was no difference in Treg
percentage in the CRC tumors compared to PBL. In both
tumor types, Treg infiltrating the tumor were qualitatively
different expressing higher levels of activation markers
when compared to blood. These data show that proteins
associated with a highly suppressive Treg phenotype
[6,7,16,17] were more abundant in T cells that infiltrateCD4+ CD25high and CD127low Treg were sorted for HLA-DR+/−. Their
s INFγ secretion by effector CD4+ T cells. Panel A and B represent 2
Figure 5 CD8+ T cells phenotype in CRC and OVC patients. A. An example of flow cytometric analysis of CD3+ CD8+ T cells analyzed for CD28
and Ki-67, upper panels, and HLA-DR and CD38, lower panels. Percentage of Ki-67+ CD8 T cells in CRC samples (n = 16) B. and OVC samples (n = 22)
C. Co-expression of CD38 and HLA-DR on CD8+ T cells in CRC samples (D) and OVC samples (E).
Kovacsovics-Bankowski et al. Journal for ImmunoTherapy of Cancer 2014, 2:38 Page 8 of 12
http://www.immunotherapyofcancer.org/content/2/1/38tumors when compared to peripheral blood. These results
also suggest that there is a selective accumulation of acti-
vated Treg within the tumor microenvironment regardless
of the tumor type or location; primary or secondary site.
These findings may lend credence to the hypothesis that
the immune system fails to immunologically reject tumors
because highly activated Treg are suppressing effector
responses within the tumor microenvironment. Others
have shown that the some of proteins studied within this
manuscript mark Treg with a greater suppressive capacity
[21,22]. This is an observation we confirmed by showing
that sorted HLA-DR+ Treg were more suppressive when
compared to HLA-DR− Treg in two OVC patient tumor
samples. Recent studies have shown that Treg isolated
from CRLM have potent immune suppressive properties
[27,28]. These studies did not analyze the phenotype of
the Treg population, but they clearly demonstrated thatTreg isolated from CRLM were more suppressive than
Treg from PBL or tumor non-invaded tissue. We also
found that infiltrating lymphocytes from both tumor types
had a higher CD8/CD4 T cell ratio compared to PBL (see
Table 1). Moreover, the CD8+ T cells within the tumor
showed a greater propensity towards activation as mea-
sured by increased co-expression of CD38/HLA-DR. There
was also an increased frequency of Ki-67+ CD8+ T cells in
the TIL compared to PBL. While there is an increase in
CD8 T cell activation and proliferation among patients’
TIL, it is clearly not sufficient to eradicate the tumor. There
may be several explanations as to why these activated CD8
T cells are incapable of eradicating tumors. The CD8+
T cells within these tumors were found among suppressive
cells including Treg (Tables 4 and 5), as well as MDSC
[29] (not analyzed here), which could help to explain their
failure to eradicate the tumor. These CD8 T cells could
Figure 6 Expression of IL-6 by qPCR in PBL and TIL. CD4+ T cells were enriched from paired blood and tumor specimens and qPCR was performed
on the enriched cell populations as described in Methods. The fold difference in IL-6 message in the TIL was normalized to the paired PBL in CRC
samples (A) and OC samples (B).
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Tim-3 (not assessed in this study), which could also limit
their functional activity as shown by others [30,31]. An-
other possibility is that the cytokine milieu created by cells
within the tumor microenvironment could have suppres-
sive effects on T cell function. Hence, we also investigated
levels of cytokine transcripts produced by CD4+ TIL iso-
lated from progressively growing tumors. While we have
found an increase in activated Treg, we also found that the
CD4+ TIL express higher levels of IL-6 mRNA compared
to CD4+ PBL. The increased expression of IL-6 mRNA ob-
served within the tumor, if translated to protein, could also
contribute to an immune-suppressed environment poten-
tially through increased pSTAT3 upregulation within im-
mune cells found in the tumor [32-34].
The two patient populations in this study had different
clinical treatment histories. The CRLM patients typically
had a preexisting history of cancer prior to the metastatic
cancer resection, and in most cases had undergone previ-
ous resection of their primary tumor followed by chemo-
therapy (Table 1). In contrast, the patients with ovarian
cancer typically had no treatment prior to their cytore-
ductive surgery. The tumor types analyzed also varied by
stage of tumor development; liver metastatic tissue for CRC
and primary tumors, omental metastases, and/or ascites for
OVC patients. However, despite these differences, we
observed many similarities in the TIL composition that
were noted across different tumor types and sites of tumor
growth.
Using a 10-color flow panel we provide a detailed ana-
lysis of the TIL composition from two different tumor
types and found as expected that the TIL phenotype is
much different than that of PBL. We can use these analyses
as a phenotypic template of TIL isolated from progressivelygrowing tumors and in the future compare these results
to the phenotype of TIL isolated from patients treated
with immunotherapy (e.g. anti-CTLA-4, anti-PD-1 and
anti-OX40). Understanding how immunotherapies work by
potentially changing the TIL composition and phenotype
could lead to a more mechanistic approach to tumor im-
munotherapy, as most of the analyses in immunotherapy
trials to date have analyzed PBL. This work also serve as a
detailed platform for understanding the T cell phenotypes
within progressively growing tumors and future studies will
investigate the T cell phenotypes from other human malig-
nancies in order determine similarities and differences to
the results shown in this study. Ultimately, a greater under-
standing of the frequency and function of T cell infiltrates
within progressively growing human tumors will allow
us to better understand how to treat patients with im-
munotherapy to elicit T cell responses with greater clinical
efficacy.
Conclusion
The results presented in this study show that the com-
position of immune infiltrates isolated from patients har-
boring different tumor types is very similar. We found
that both colorectal liver metastases and ovarian cancer
have a greater percentage of activated T regulatory cells
as well as a higher percentage of activated CD8+ T cells
when compared to peripheral blood of the same patients.
We also found that CD4 T cells isolated from both tumor
types have an increase in mRNA for IL-6 compared to
peripheral blood CD4 T cells. This manuscript provides a
foundation for the activation profile of tumor infiltrating
T cells in two different progressively growing tumor types
and could be used as baseline when assessing immuno-
logic changes in patients treated with immunotherapy.
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Collection and isolation of lymphocytes from peripheral
blood and ascites
Peripheral blood was collected in heparinized tubes just
prior to or during surgery. Ascites cells were centrifuged
and the pellet was resuspended in XVivo media (Lonza) and
mononuclear leukocytes were separated from red blood cells
and or tumor cells by Ficoll-Paque Plus (GE Healthcare,
17-1440-02) density gradient centrifugation for both asci-
tes and peripheral blood. The leukocyte fraction was har-
vested, washed in PBS and counted prior to being stained
or enriched.Isolation of tumor-infiltrating lymphocytes
Specimens were obtained at the time of surgery. Single
cell suspension were obtained under sterile conditions in
PBS, solid tumors were cut into 1-3 mm3 pieces and
digested at room temperature for 1 hour on a magnetic
stirring apparatus in a solution containing DNAse (Roche,
4536282001), collagenase (Sigma, C5138), halyuronidase
(Sigma, H-6254) as well as human albumin (CSL Behring,
0053-7680-32) in RPMI (Lonza, 12-702Q). Enzymatically
dissociated tumor was filtered through a 70 μm filter. Fil-
tered samples were then diluted 1:2 with RPMI and ficolled
as described above to obtain a leukocyte-enriched fraction.
Cells were then washed three times in PBS (1st wash @
1,000 rpm for 10 minutes to remove debris, then 2x
@1,250 for 5 minutes) and counted. Leukocytes were
resuspended at 10 × 106 cells/ml in PBS prior to staining
or enrichment.Flow cytometry analysis
Single cell suspensions of leukocytes from blood, ascites,
tumor or omental metastases were stained with the fol-
lowing monoclonal antibodies: anti-CD3 APC-H7 (BD
Pharmingen, 560176), anti-CD4 eFlour 450 (eBioscience,
48-0048-42), anti-CD8 Pacific Orange (Invitrogen, MH
CD0830), anti-CD25 APC (BD Pharmingen, 555434), or
anti-CTLA-4 APC (BD Pharmingen, 555855), anti-CD28
PerCpCy5.5 (eBioscience, 45-0289-42), anti-CD38 PE-TR
(Invitrogen, MHCD3817), anti-HLA-DR PE-Cy7 (BD Bio-
sciences, 335795), anti-FoxP3 PE (eBioscience, 12-4777-
42), anti-ki67 FITC (BD Pharmingen, 556026) or CD39
FITC (BD Pharmingen, 561444) or anti-Helios (Biolegend,
137214). Cells were stained in FACs buffer (1%FBS in PBS
with 0.01%NaN3) and fixed according to the ebioscience
FoxP3 Fix-Perm kit protocol (eBioscience, 00-5521-00). All
samples were run on a BD LSRII Flow cytometer and
analysed by FACSDiva BD. Briefly, for every single flow
cytometric antibody, we have used Fluorescent Minus
One (FMO), to discriminate between positive and nega-
tive cells [35].Treg sort
Lymphocytes from ascites, prepared as described above,
were stained with anti-CD3, anti-CD4, anti-CD25, anti
CD127 and anti-HLA-DR and sorted for T effector cells
(CD3+, CD4+, CD25low and CD127high) and Treg: CD3+,
CD4+, CD25high, CD127low and HLA-DR+ and CD3+, CD4+,
CD25high, CD127low and HLA-DR−. Cells were sorted
on an Aria sorter (BD).
Treg suppressive assay
Effector (30–50,000/well) and Treg were plated at ratio
described in Figure 4, and stimulated with soluble anti-
CD3 (1 μg/ml) and CD28 (2 μg/ml) as previously described
[36]. Supernatents were harvested at Day 3 and 5 and IFNγ
was measured by ELISA (eBioscience).
CD4 enrichment
Enrichment of CD4+ T cells from blood and tumor sam-
ples was achieved using the EasySep Human CD4 Nega-
tive Enrichment kit (StemCell Technologies, 19052). The
CD4 population was further purified, using the EasySep
Human CD4 Positive Selection kit (StemCell Technologies,
18052).
qPCR
The RNA from CD4+ lymphocyte populations was isolated
using the QIAshredder (QIAGEN, 79654) and RNeasy
Mini kits (QIAGEN, 74104). The isolated RNA was treated
with Turbo DNase (Ambion, AM1907) and quantified by
optical density. 1 μg of treated RNA was used to prepare
cDNA using the RevertAid First Strand cDNA Synthesis
kit (Fermentas, K1621). Samples were then analyzed by
qPCR on the Applied Biosystems Step One Plus using
250 ng of cDNA per reaction with reactions set up in
triplicate. The reactions utilized the Maxima Probe/ROX
qPCR Master Mix (Fermentas, K0232). Samples were
analyzed using FAM/TAMRA probes for IL-6 expression
(Invitrogen, Hs00985639_m1), IL-17 expression (Invitro-
gen, Hs00174383_m1) and IFNγ expression (Invitrogen,
Hs00989291_m1). GAPDH was used as the endogenous
mRNA control (Invitrogen, Hs02758991_g1). cDNA from
normal donor PBMCs stimulated with PMA/ionomycin
for 11 hours was used as the calibrator sample. The results
were then analyzed using the Comparative Ct Method of
relative quantification.
Additional files
Additional file 1: Figure S1. Flow cytometry gating strategy. Tumor
samples were processed as described in Methods. Single cell suspensions
were analyzed by flow cytometry. FSC and SSC were used to determine the
lymphocyte population. CD3+ T cells were subdivided into CD4+ and CD8+
T cells. CD4+T cells were analyzed for the expression of CD25 and FoxP3
(Treg). CD39, HLA-DR, CTLA-4 and Helios were used to characterize highly
suppressive Treg. Both non-Treg and Treg were assessed for proliferation by
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http://www.immunotherapyofcancer.org/content/2/1/38using Ki-67. Expression of CD38 and HLA-DR on CD8+ T cells was
used to characterize recently activated CD8+ T cells and Ki-67 identified
proliferating CD8+ T cells.
Additional file 2: Figure S2. HLA-DR+ TIL Treg have a higher potency
to suppress INFγ secretion. CD3+, CD4+, CD25high and CD127low Treg were
sorted for HLA-DR+/−. They were co-cultured in triplicate with CD4
+ CD25− T
cells at different cell ratio. INFγ secretion was measured in the supernatant by
ELISA. Panel A and Panel B represent 2 individual patients.
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